CD56 may be a more useful immunohistochemical marker than somatostatin receptor 2A for the diagnosis of phosphaturic mesenchymal tumors.
Phosphaturic mesenchymal tumors (PMTs) are the most typical cause of tumor-induced osteomalacia (TIO) associated with mesenchymal neoplasms. Specifically, TIO is attributed to the production of phosphatonins, such as fibroblast growth factor 23 (FGF23), participating in the homeostasis of phosphate. Although immunohistochemistry (IHC) for FGF23 showed characteristic positive staining in PMTs, FGF23 antibodies that can be used for the reliable diagnosis of PMTs are hard to obtain in common pathology laboratories. Somatostatin receptor 2A (SSTR2A) has been previously proposed as an alternatively useful marker for the diagnosis of PMTs. However, SSTR2A is not commonly utilized in pathological laboratories. The CD56 marker is a useful alternative that is comparable to SSTR2A and is similar considering the sensitivity. Even in cases of PMTs originating in the bones, ethylenediaminetetraacetic acid-based decalcification for tissue processing does not seem to affect the IHC of CD56. As CD56 immunopositivity in mesenchymal tumors is limited, it also has some degree of specificity for PMTs. Thus, when PMTs are suspected, the use of CD56 is recommended.
Department of Pathology, Graduate School of Medicine, The University of Tokyo Tokyo, Japan.
Shogo
S
Tajima
Department of Pathology, Graduate School of Medicine, The University of Tokyo Tokyo, Japan.
Masashi
M
Fukayama
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D019002:CD56 Antigen / Q000032:analysis*; D005260:Female; D000089703:Fibroblast Growth Factor-23; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008637:Mesenchymoma / Q000737:chemistry* / Q000473:pathology; D008875:Middle Aged; D009372:Neoplasms, Connective Tissue / Q000737:chemistry* / Q000473:pathology; D010018:Osteomalacia; D010257:Paraneoplastic Syndromes; D011237:Predictive Value of Tests; D017481:Receptors, Somatostatin / Q000032:analysis*
D014408:Biomarkers, Tumor; D019002:CD56 Antigen; C000717427:FGF23 protein, human; C522918:NCAM1 protein, human; D017481:Receptors, Somatostatin; D000089703:Fibroblast Growth Factor-23; C093733:somatostatin receptor 2
CD56; FGF23; Phosphaturic mesenchymal tumor; SSTR2A; immunohistochemistry